{"id":1599,"date":"2002-03-01T12:06:00","date_gmt":"2002-03-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/schutz-von-daten-oder-schutz-von-legenden"},"modified":"2002-03-01T12:06:00","modified_gmt":"2002-03-01T11:06:00","slug":"schutz-von-daten-oder-schutz-von-legenden","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/schutz-von-daten-oder-schutz-von-legenden","title":{"rendered":"Schutz von Daten oder Schutz von Legenden?"},"content":{"rendered":"<p>Pharmafirmen haben erfolgreich verhindert, da\u00df Wissenschaftler von NICE (National Institute for Clinical Excellence, das sich um Therapiestandards in Gro\u00dfbritannien bem\u00fcht) die Patientendaten aus den Beta-Interferon-Studien bei Multipler Sklerose (MS) einsehen d\u00fcrfen (Burke, K.: http:\/\/bmj.com\/cgi\/content\/full\/324\/7333\/320\/b). Die Anwendung von Interferon beta bei MS ist umstritten, da der Langzeitnutzen zweifelhaft ist, die Therapiekosten aber eminent hoch sind. Die [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharmafirmen haben erfolgreich verhindert, da\u00df Wissenschaftler von NICE (National Institute for Clinical Excellence, das sich um Therapiestandards in Gro\u00dfbritannien bem\u00fcht) die Patientendaten aus den Beta-Interferon-Studien bei Multipler Sklerose (MS) einsehen d\u00fcrfen (Burke, K.: http:\/\/bmj.com\/cgi\/content\/full\/324\/7333\/320\/b). Die Anwendung von Interferon beta bei MS ist umstritten, da der Langzeitnutzen zweifelhaft ist, die Therapiekosten aber eminent hoch sind. Die [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3734,3297,352,3735,1409],"class_list":["post-1599","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-datenschutz","tag-interferon-beta","tag-multiple-sklerose","tag-nice","tag-studien"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1599"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1599\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}